Overall, this study provides exciting preclinical data that expands the potential utility of PIM inhibitors in PCa as antimetastatic agents that could reduce the invasive potential of prostate tumors, resulting in lower patient mortality. This evidence concerns the gene PIM1 and prostate neoplasm.